Koschwanez Heidi E, Reichert William M
Department of Biomedical Engineering, Duke University, 136 Hudson Hall, Box 90281, Durham, NC 27708, USA.
Biomaterials. 2007 Sep;28(25):3687-703. doi: 10.1016/j.biomaterials.2007.03.034. Epub 2007 Apr 19.
To date, there have been a number of cases where glucose sensors have performed well over long periods of implantation; however, it remains difficult to predict whether a given sensor will perform reliably, will exhibit gradual degradation of performance, or will fail outright soon after implantation. Typically, the literature emphasizes the sensor that performed well, while only briefly (if at all) mentioning the failed devices. This leaves open the question of whether current sensor designs are adequate for the hostile in vivo environment, and whether these sensors have been assessed by the proper regimen of testing protocols. This paper reviews the current in vitro and in vivo testing procedures used to evaluate the functionality and biocompatibility of implantable glucose sensors. An overview of the standards and regulatory bodies that govern biomaterials and end product device testing precedes a discussion of up-to-date invasive and non-invasive technologies for diabetes management. Analysis of current in vitro, in vivo, and then post explantation testing is presented. Given the underlying assumption that the success of the sensor in vitro foreshadows the long-term reliability of the sensor in the human body, the relative merits of these testing methods are evaluated with respect to how representative they are of human models.
迄今为止,已有许多葡萄糖传感器在长时间植入过程中表现良好的案例;然而,要预测某一特定传感器是否能可靠运行、性能是否会逐渐下降,或者在植入后不久就完全失效,仍然很困难。通常,文献强调的是表现良好的传感器,而对于失效的设备只是简要提及(如果提及的话)。这就留下了一个问题:当前的传感器设计是否足以应对恶劣的体内环境,以及这些传感器是否经过了适当的测试方案评估。本文回顾了目前用于评估可植入葡萄糖传感器功能和生物相容性的体外和体内测试程序。在讨论最新的糖尿病管理侵入性和非侵入性技术之前,先概述了管理生物材料和最终产品设备测试的标准和监管机构。文中还介绍了当前体外、体内以及植入后测试的分析情况。鉴于传感器在体外的成功预示着其在人体中的长期可靠性这一基本假设,对这些测试方法的相对优点根据它们对人体模型的代表性进行了评估。